BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.

BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.

Intravesical Bacillus Calmette Guérin (BCG) immunotherapy is considered the standard of care for treatment of non-muscle invasive bladder cancer; however the treatment parameters were established empirically. In order to evaluate potential optimization of clinical parameters of BCG induction therapy...

Full description

Bibliographic Details
Main Authors:	Cyrill A Rentsch, Claire Biot, Joël R Gsponer, Alexander Bachmann, Matthew L Albert, Romulus Breban
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3581521?pdf=render

Similar Items

Bladder Cancer Immunotherapy: BCG and Beyond
by: Eric J. Askeland, et al.
Published: (2012-01-01)

Mechanisms of Resistance to BCG Immunotherapy in Bladder Cancer
by: Rouanne, Mathieu
Published: (2019)

The results of treatments and complications of immunotherapy (BCG and alpha-interferon) in superficial TCC of bladder
by: Jabalameli P, et al.
Published: (1994-04-01)

Dactilitis and oligoarthritis after BCG immunotherapy in a patient affected by bladder cancer
by: N. Elkhaldi, et al.
Published: (2011-09-01)

BCG immunotherapy for superficial bladder cancer: further insights into its mechanism of action
by: Zlotta, Alexandre

Intravesical application of Gemicitabine for superficial bladder cancer resistant to intrvesical immunotherapy with BCG vaccine
by: I. V. Seregin, et al.
Published: (2020-02-01)

BCG-THERAPIE ET CANCER DE LA VESSIE : LA CARACTERISATION ET LA MODELISATION DE LA REPONSE IMMUNE AU BCG DANS LA VESSIE REVELENT DES STRATEGIES POUR L'AMELIORATION DE LA REPONSE ANTI-TUMORALE
by: Biot, Claire
Published: (2012)

Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy
by: Raffaella Rossi, et al.
Published: (2013-12-01)

Miliary Tuberculosis Due to BCG Immunotherapy
by: Bilgehan AYGEN, et al.
Published: (1996-03-01)

Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy
by: Wojciech Krajewski, et al.
Published: (2020-04-01)

Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer
by: Mateusz Adamkiewicz, et al.
Published: (2021-03-01)

Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease
by: Danielle Klinger, et al.
Published: (2021-05-01)

MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model
by: Nina M. G. P. de Queiroz, et al.
Published: (2021-08-01)

Stability Analysis of Delayed Tumor-Antigen-ActivatedImmune Response in Combined BCG and IL-2Immunotherapy of Bladder Cancer
by: Svetlana Bunimovich-Mendrazitsky, et al.
Published: (2020-11-01)

Recognition and Treatment of BCG Failure in Bladder Cancer
by: Andrew J. Lightfoot, et al.
Published: (2011-01-01)

BCG Induced Necrosis of the Entire Bladder Urothelium
by: Malte Krönig, et al.
Published: (2015-09-01)

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
by: Wojciech Krajewski, et al.
Published: (2020-10-01)

Health newscasts for increasing influenza vaccination coverage: an inductive reasoning game approach.
by: Romulus Breban
Published: (2011-01-01)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01)

Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer.
by: Kathrin Buffen, et al.
Published: (2014-10-01)

INTRAVESICULAR IMMUNOTHERAPY WITH BCG VACCINE AND INTERFERON-αα2B FOR NON-INVASIVE CARCINOMA OF THE URINARY BLADDER: RESULTS OF PROSPECTIVE RANDOMIZED STUDY
by: A. A. Minich, et al.
Published: (2014-07-01)

Does restaging transurethral resection of bladder tumor influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years’ experience
by: Wojciech Krajewski, et al.
Published: (2018-12-01)

INTRAVESICULAR IMMUNOTHERAPY WITH BCG VACCINE AND INTERFERON-αα2B FOR NON-INVASIVE CARCINOMA OF THE URINARY BLADDER: RESULTS OF PROSPECTIVE RANDOMIZED STUDY
by: A. A. Minich, et al.
Published: (2014-07-01)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
by: Chun Jye Lim, et al.
Published: (2021-01-01)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
by: Uyen To, et al.
Published: (2014-01-01)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
by: S. Lukacs, et al.
Published: (2013-01-01)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
by: Andres F. Correa, et al.
Published: (2015-01-01)

Immunotherapy for bladder cancer
by: Fuge O, et al.
Published: (2015-05-01)

Methylation status as a predictor of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor
by: Petr Husek, et al.
Published: (2017-06-01)

Delayed cystectomy for T 1 G 3 TCC of urinary bladder managed initially by TURBT & intravesical immunotherapy (BCG + interferon) rationale & our result
by: N K Mohanty, et al.
Published: (2004-01-01)

BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy
by: Alvaro Morales, et al.
Published: (2020-07-01)

Reiter’s syndrome occurred following intravesical BCG immunotherapy: Case presentation
by: Fatih Elbir, et al.
Published: (2015-06-01)

Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer
by: Rui Cao, et al.
Published: (2021-09-01)

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)

LEGAL BASIC OF BCG-THERAPY FOR BLADDER CANCER IN MUNICIPAL POLYCLINICS
by: M. M. Zorina, et al.
Published: (2016-10-01)

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)

Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect
by: Jiansong Han, et al.
Published: (2020-09-01)

Adenovirus-mediated CD40 Ligand Immunotherapy of Prostate and Bladder Cancer
by: Dzojic, Helena
Published: (2007)

BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis
by: Hermann Inge-Marie, et al.
Published: (2010-06-01)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
by: Ashish M. Kamat, et al.
Published: (2017-08-01)